This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prolonged neonatal jaundice

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Prolonged jaundice is defined as jaundice lasting for longer than:

  • 14 days in term infants
  • 21 days in preterm infants

The first investigation is to assay the proportion of conjugated bilirubin.

Possible causes include:

  • urinary tract infection
  • hypothyroidism
  • galactosaemia
  • breast milk jaundice

NICE suggest (1) that in babies with a gestational age of 37 weeks or more with jaundice lasting more than 14 days, and in babies with a gestational age of less than 37 weeks and jaundice lasting more than 21 days:

  • look for pale chalky stools and/or dark urine that stains the nappy

  • measure the conjugated bilirubin

  • carry out a full blood count

  • carry out a blood group determination (mother and baby) and DAT (Coombs' test). Interpret the result taking account of the strength of reaction, and whether mother received prophylactic anti-D immunoglobulin during pregnancy

  • carry out a urine culture

  • ensure that routine metabolic screening (including screening for congenital hypothyroidism) has been performed.

Follow expert advice about care for babies with a conjugated bilirubin level greater than 25 micromol/litre because this may indicate serious liver disease

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.